- Pharmacy services developer Avricore Health is establishing a network of lab-grade testing and reporting for select medical conditions through neighborhood pharmacy stores
- Such neighborhood POC store solutions building empowers patients to work with trained pharmacy professionals in monitoring select health conditions, including virus exposure
- Viruses have become a focal point of health response efforts during the past two years as COVID-19 SARS-CoV-2 infections have claimed millions of lives and sickened scores of others
- Avricore has thus far established its pilot program in Canada’s eastern Ontario province and western British Columbia province, anticipating strong growth of the HealthTab network in Canada and internationally in 2023
The global COVID health crisis has illuminated the importance of the medical sciences like never before as the populations of virtually every nation have monitored news updates on the progress of infectious disease rates, visited local health departments to receive vaccinations, and debated the effectiveness of health policy measures on social media.
The vaccination efforts by local health departments have extended to the street, with mobile shot clinics and education strategies independent of primary caregiver offices. In real time, the organization of the COVID response plan has demonstrated the potential of point-of-care (“POC”) testing and POC analysis of lab results.
Americans interested in the advent of COVID-19 home test kits have overwhelmed resources in many places, particularly as the holiday season has generated a spike in family and neighbor gatherings to celebrate, leading major pharmacy chains to ration individual purchases of the kits (https://ibn.fm/aEalA).
Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a health diagnostics solutions innovator dedicated to expanding access to lab-grade medical test results for a wide variety of medical conditions, including potential COVID analysis.
Avricore’s trademarked HealthTab platform brings together a baker’s list of corporate resources that make up the recipe for patients’ active participation in their own medical care.
Multinational medical devices and health care company Abbott Laboratories has agreed to let Avricore distribute its handheld blood chemistry analyzer, for example, under Avricore’s pilot rollout of its accessible lab test program at several Canadian Shoppers Drug Mart pharmacies, using Abbott’s trademarked ID Now kiosks. HealthTab provides the nerve fibers through which the program’s messages travel.
“We‘ve demonstrated a unique resilience by remaining focused on our goal of creating the world’s largest rapid testing network in pharmacy,” Avricore Health CEO Hector Bremner stated earlier this year (https://ibn.fm/9Rk8q). “We are well on our way to making actionable health information more accessible for everyone and dramatically expanding our network in the coming months.”
In the process, Avricore is simultaneously rewarding patients interested in maintaining their well-being and pharmacies concerned about their bottom line, particularly in Canada where passage of the Pan-Canadian Select Molecule Price Initiative for Generic Drugs in 2018 turned out to be a money-losing effort for the corner drug stores as it reduced retail margins in reimbursements.
The HealthTab platform provides lab results for monitoring pre-diabetes and cardiovascular conditions, as well as viruses such as COVID’s SARS-CoV-2, RSV, influenza A and B, and strep.
As enthusiasm for point-of-care testing continues to grow, patients find it easier to visit a neighborhood pharmacy and monitor their blood chemistry on a regular basis to identify concerns in regard to their own conditions.
For more information, visit the company’s website at www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.